Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerry Bagel

Showing results (71-80 of 100) with videos related to

Pageof 10
Sort By:
Journal of the American Academy of Dermatology|December 26, 2024
Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: Week 52 results from a phase 3b, randomized, double-blind, placebo-controlled trialHoward L Sofen, Kurt Gebauer, Lynda Spelman, et al.
The British Journal of Dermatology|January 4, 2022
Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trialMatthias Augustin, Kristian Reich, Paul Yamauchi, et al.
Dermatology and Therapy|October 19, 2018
Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)Jerry Bagel, John Nia, Peter W Hashim, et al.
Journal of Drugs in Dermatology : JDD|August 16, 2021
Serious Gastrointestinal-Related Adverse Events Among Psoriasis Patients Treated With Guselkumab in VOYAGE 1 and VOYAGE 2Peter Foley, Kristian Reich, Andrew Blauvelt, et al.
Journal of the American Academy of Dermatology|February 18, 2026
The 487-gene expression profile test guides systemic therapy selection to improve outcomes for patients with atopic dermatitis: Results from a prospective trialJonathan I Silverberg, Lawrence F Eichenfield, April W Armstrong, et al.
Dermatology and Therapy|May 19, 2022
Baseline Demographics and Severity and Burden of Atopic Dermatitis in Adult Patients Initiating Dupilumab Treatment in a Real-World Registry (PROSE)Jerry Bagel, Tien Q Nguyen, Hermenio Lima, et al.
Journal of the American Academy of Dermatology|November 16, 2024
FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasisLaura K Ferris, Jerry Bagel, Yu-Huei Huang, et al.
The New England Journal of Medicine|April 23, 2021
Bimekizumab versus Adalimumab in Plaque PsoriasisRichard B Warren, Andrew Blauvelt, Jerry Bagel, et al.
Cutis|November 6, 2010
Optimizing topical therapies for treating psoriasis: a consensus conferenceJoshua A Zeichner, Mark G Lebwohl, Alan Menter, et al.
The Journal of Dermatological Treatment|August 5, 2021
Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE studyAndrew Blauvelt, April W Armstrong, Richard G Langley, et al.
Pageof 10

Showing results (71-80 of 100) with videos related to

Sort By:
Pageof 10
Journal of the American Academy of Dermatology|December 26, 2024
Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: Week 52 results from a phase 3b, randomized, double-blind, placebo-controlled trialHoward L Sofen, Kurt Gebauer, Lynda Spelman, et al.
The British Journal of Dermatology|January 4, 2022
Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trialMatthias Augustin, Kristian Reich, Paul Yamauchi, et al.
Dermatology and Therapy|October 19, 2018
Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)Jerry Bagel, John Nia, Peter W Hashim, et al.
Journal of Drugs in Dermatology : JDD|August 16, 2021
Serious Gastrointestinal-Related Adverse Events Among Psoriasis Patients Treated With Guselkumab in VOYAGE 1 and VOYAGE 2Peter Foley, Kristian Reich, Andrew Blauvelt, et al.
Journal of the American Academy of Dermatology|February 18, 2026
The 487-gene expression profile test guides systemic therapy selection to improve outcomes for patients with atopic dermatitis: Results from a prospective trialJonathan I Silverberg, Lawrence F Eichenfield, April W Armstrong, et al.
Dermatology and Therapy|May 19, 2022
Baseline Demographics and Severity and Burden of Atopic Dermatitis in Adult Patients Initiating Dupilumab Treatment in a Real-World Registry (PROSE)Jerry Bagel, Tien Q Nguyen, Hermenio Lima, et al.
Journal of the American Academy of Dermatology|November 16, 2024
FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasisLaura K Ferris, Jerry Bagel, Yu-Huei Huang, et al.
The New England Journal of Medicine|April 23, 2021
Bimekizumab versus Adalimumab in Plaque PsoriasisRichard B Warren, Andrew Blauvelt, Jerry Bagel, et al.
Cutis|November 6, 2010
Optimizing topical therapies for treating psoriasis: a consensus conferenceJoshua A Zeichner, Mark G Lebwohl, Alan Menter, et al.
The Journal of Dermatological Treatment|August 5, 2021
Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE studyAndrew Blauvelt, April W Armstrong, Richard G Langley, et al.
Pageof 10